Johnson NW. Epidemiology of oral cancer in risk markers of oral disease. In: Johnson NW, ed. Oral Cancer, Vol. 2. Cambridge, UK: Cambridge University Press, 1991: 3–26.
Devesa SS, Silverman DT, Young JL Jr, et al. Cancer incidence and mortality trends among whites in the United States 1947–1984. JNCI 1987; 4: 701–770.
Voravud N. Cancer in the far east. In: Sikara K, Halnan KE, eds. Treatment of Cancer, Second Edition. London, UK: Chapman and Hall Medical, 1990: 887–894.
Wolf G, Lippman SM, Laramore G, et al. Head and neck cancer. In: Holland JF, Frei E, Bast RC Jr, Kufe DW, Morton DC, Weischelbaum R, eds. Cancer Medicine, Third Edition. Philadelphia, PA (USA): Lea and Febiger, 1990: 887–894.
Binnie WH, Cawson RA, Hill GB, Soaper AE. Oral cancer in England and Wales. Series SMPS No. 23. London, UK: HMSO, 1972: 25–48.
Silberberg E, Lubera J. Cancer Statistics 1987, CA. 1987; 37: 2–9.
Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother 1988; 22: 333–338.
Creaven PJ, Rustum YM, Petrelli NJ, Gorbunova VA. Clinical studies of the modulation of Ftorafur. In: Rustum YM, ed. Novel Approaches to Selective Treatments of Human Solid tumors: Laboratory and Clinical Correlation. New York, NY (USA): Raven Press, 1993: 253–262.
Yamanoto J, Toide K, Haruno A, Yoshimura Y, Unemi N. General pharmacological properties of UFT, a new type of anticancer agent consisting of 1(2-tetrahydrofurayl)-5-fluorouracil (FT) and uracil. Drug Res 1981; 31: 1268–1278.
Hiller SA, Zhuk RA, Lidaks M, Ziderman A. Analogs of pyrimidine nucleoside. 1. N1-(α-tetrahydrofuryl) derivatives of natural pyrimidine bases and their metabolites. Dokl Akad Natuk SSSR 1967; 176: 332–335.
Smolyanskaya AZ, Tugarinor OA. The biological activity of antitumour antimetabolite ‘Ftorafur’. Neoplasma 1972; 19: 341–345.
Fujii S, Kitano S, Ikenaka K, Shirasaka T. Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2′-tetrahydrofuranyl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979; 70: 209–214.
Okamoto H, Shoin S, Koshimura S, Shimizu R. Studies on the anticancer and streptolysin S-forming ability of hemolytic streptococci. Jpn J Microbiol 1967; 11: 323–336.
Ono T, Kurata S, Wakabayashi K, Sugawara, Y, Saito M, Ogawa H. Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumor cells in vitro. Gann 1973; 64: 59–69.
Sakurai Y, Tsukagoshi S, Satoh H, Akiba T, Suzuki S, Takagashi Y. Tumor-inhibitory effect of a streptococcal preparation (NSC-B116209). Cancer Chemother Rep 1972; 56: 9–17.
Okamoto H, Shoin S, Koshimura, S. Streptolysin S-forming and anticancer activities of group A streptococci. In: Jeljaszewicz J, Wadstrom T, eds. Bacterial Toxin and Cell Membranes. New York, NY (USA): Academic Press, 1978: 259–289.
Ishii Y, Yamaoka H, Toh K, Kikuchi K. Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432. Gann 1976; 67: 115–119.
Oshimi K, Kano S, Takaku F, Okumura K. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. JNCI 1980; 65: 1265–1269.
Oshimi K, Wakasugi H, Seki H, Kano S. Streptococcal preparation OK-432 augments cytotoxic activity against an erythroleukemic cell line in humans. Cancer Immunol Immunother 1980; 9: 187–192.
Matsubara S, Suzuki F, Ishida N. Induction of immune interferon in mice treated with a bacterial immunopotentiator, OK-432. Cancer Immunol Immunother 1979; 6: 41–45.
Sato M, Yoshida H, Yanagawa T, et al. Effects of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer. Int J Oral Surg 1984; 13: 7–15.
Hoshino T, Iho S, Kura F, Uchida A. In vivo and in vitro biological effects of OK-432, a streptococcal preparation, on the augmentation of autologous tumor cell killing activity and cytokine production of lymphocytes and monocytes in malignant diseases. In: Micksche M, Klein E, eds. OK-432. A Biological Response Modifier. Tokyo, Japan: Professional Postgraduate Services, International, 1986: 61–68.
Nagamuta M, Yamamoto S, Usami Y, et al. Induction of TNF in peritoneal fluid of mice treated with OK-432. In: Ishida N, ed. Mechanisms of Antitumor Effects of OK-432. Tokyo, Japan: Excerta Medica, 1986; 126–136.
Djeu JY, Henbaugh JA, Holden HT, Herberman RB. Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol 1979; 122: 175–181.
Herberman RB, Ortaldo JR, Mantovani A, et al. Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol 1982; 67: 160–167.
Peri G, Polentaruti N, Sessa C, Mangioni C, Mantovani A. Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokine and endotoxin. Int J Cancer 1981; 28: 143–152.
Yanagawa E, Toge T, Niimoto M, Hattori T. In vitro augmentation of natural and autotumor killing activity of tumor-associated macrophages by OK-432, interleukin-2, and interferon. In: Hoshino T, ed. Immunopharmacological Aspects of OK-432 in Humans. Tokyo, Japan: Excerpta Media, 1986: 17–26.
Gidlund M, Orn S, Wizzell H, Senik A, Gresser I. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1978; 273: 759–761.
Schultz RM, Papamatheakis ID, Chirigos MA. Functional and morphologic characteristics of interferon-treated macrophages. Cell Immunol 1978; 35: 84–91.
Okamoto M, Kaji R, Kasetani H, et al. Purification and characterization of interferon-γ-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-γ-inducing activity of OK-432. J Immunother 1993; 13: 232–242.
Takada H, Kawabata Y, Arakaki R, et al. Molecular and structural requirements of a lipoteichoic acid from Enterococcus hirae ATCC 9790 for cytokine-inducing, antitumor, and antigenic activities. Infect Immun 1995; 63: 57–65.
Schwartz EL, Holfman M, O'Connor C, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 1991; 182: 1232–1239.
Cascinu S, Del Ferro E, Fedeli A, et al. Cytokinetic effects of interferon in colorectal cancer tumors: Implications in the design of the interferon/5-fluorouracil combinations. Cancer Res 1993; 53: 5429–5432.
International Union Against Cancer. TNM Classification of Malignant Tumors, 4th Edition. Oral Cavity. Geneva, Switzerland: International Union Against Cancer, 1987: 16–18.
Wahi PN, Cohen B, Luthra UK. Histological typing of oral and oropharyngeal tumors. In: World Health Organization. International Histological Classification of Tumors, No. 4. Geneva, Switzerland: WHO, 1971.
Shi SR, Key MC, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissue: an enhancement method for immunohistochemical staining based on microwave open-heating of tissue sections. J Histochem Cytochem 1991; 39: 741–748.
Hsu S-M, Ralne L, Franger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577–580.
Abe K, McKibbin J, Hakomori S. The monoclonal antibody directed to difucosylated type 2 chain (Fucα1–2Galβ1–4[Fucα1–3]GlcNAc: Y determinant. J Biol Chem 1983; 258: 11793–11797.
Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493–501.
Crowe DL, Hu L, Gudas LJ, Rheinwald JG. Variable expression of retinoic acid receptor (RAR beta) mRNA in human oral and epidermal keratinocytes; relation to keratin 19 expression and keratinization potential. Differentiation 1991; 48: 199–208.
Uchida A, Hoshino T. Clinical studies on cell-mediated immunity in patients with malignant disease. Cancer 1980; 45: 476–483.
Watanabe S, Sendo F, Kimura S, Arai S. Activation of cytotoxic polymorphonuclear leukocytes by in vitro administration of a streptococcal preparation, OK-432. JNCI 1984; 72: 1365–1370.
Saito M, Nanjo M, Aonuma E, et al. Activated macrophages are responsible for the tumor-inhibitory effect in mice receiving intravenous injection of OK-432. Int J Cancer 1984; 33: 271–276.
Talmage IE, Herberman RB. Evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep 1986; 70: 171–182.
Uchida A, Micksche M. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK-432. JNCI 1983; 71: 673–680.
Hojo H, Hashimoto Y. Cytotoxic cells induced in tumor-bearing rats by a streptococcus preparation (OK-432). Gann 1981; 72: 692–699.
Saito M, Nanjo M, Kataoka M, et al. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice. Cancer Res 1988; 48: 4163–4167.
Moriya Y, Sato H, Ito K, Saito M, Yoshida T, Ishida T. Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice. Cancer Immunol Immother 1993; 36: 245–250.
Hayashi Y, Nishida T, Yoshida H, et al. Peripheral K-lymphocyte population in head and neck cancer. Cancer 1984; 53: 2507–2514.
Hayashi Y, Yoshida H, Yamashita T, et al. Phenotypic and functional characterization of peripheral natural killer cell population in squamous cell head and neck cancer. Cancer J 1987; 1: 353–357.
Sato M. Treatment of oral cancer. Asian J Oral Maxillofac Surg 1993; 5: 87–99.
Pak AS, Wright MA, Matthews JP, et al. Mechanisms of immune suppression in patients with head and neck cancer: Presence of CD34+ cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clinical Cancer Res 1995; 1: 95–103.
Pak AS, Ip G, Wright MA, Young MRI. Treating tumor-bearing mice with low-dose γ-interferon plus tumor necrosis factor α to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy. Cancer Res 1995; 55: 885–890.
Letessier EM, Sacchi M, Joshson JT, Herberman RB, Whiteside TL. The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Cell Immunol 1990; 130: 446–458.
Dziarski R, Gupta D. Heparin, sulfatd heparinoids, and lipoteichoic acids bind to 70-kDa peptidoglycan/lipopolysaccharide receptor protein on lymphocytes. J Biol Chem 1994; 269: 2100–2110.
Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil action against various cancer cells. Jpn J Cancer Res 1990; 81: 1039–1044.
Inaba M, Mitsuhashi J, Ozawa S. Kinetic analysis of 5-fluorouracil action against various cancer cells. Jpn J Cancer Res 1990; 81: 1039–1044.
Inaba M, Mitsuhash J. Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. Oncol Res 1994; 6: 303–309.
Waxman S, Scher BM, Hellinger N, Scher W. Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide. Cancer Res 1990; 50: 3878–3887.
Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 959–967.
Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40: 2353–2362.
Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50: 3473–3486.
Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769–1775.
Pazdur R, Ajani JA, Patt YZ, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990; 8: 2027–2031.
Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1991; 9: 1806–1810.
Schwartz EL, Hoffman M, O'Connor C, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 1991; 182: 1232–1239.
Vogelstein B. Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523–526.
Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304–6311.
Nagasawa H, Robertson J, Arundel CS, Little JB. The effect of X-irradiation on the progression of mouse 10T1/2 cells released from density-inhibited cultures. Radiat Res 1984; 97: 537–545.
Kuerbitz L, Plunkett BS, Walsh WW, Kastan MB. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89: 7491–7495.
Ward JF. DNA damage as the cause of ionizing radiation-induced gene activation. Radiat Res 1994; 138(Suppl 1): S85–S88.
Jung M, Notario V, Dritschilo, A. Mutations in the p53 gene in radiation-sensitive and-resistant human squamous carcinoma cells. Cancer Res 1992; 52: 6390–6393.
Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993; 53: 3667–3669.
Morris GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 1989; 264: 13856–13864.
Mercer WE, Shields MT, Lin D, Appella E, Ullrich SL. Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci USA 1991; 88: 1958–1962.
Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285–294.
Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immnochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893–899.
Chen PI, Chen Y, Bookstein R, Lane DP. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576–1580.
Marks J, Davidoff A, Kerns B, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51: 2979–2984.
Visakori T, Kallinoiemi OP, Heikkinen AT, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. JNCI 1992; 84: 883–887.
Hiraishi K, Suzuki K, Hakomori SI, Adachi M. LeY antigen expression is correlated with apoptosis (programmed cell death). Glycobiology 1993; 3: 381–390.